Novel inhibitors of the early steps of the HIV-1 life cycle

Expert Opinion on Investigational Drugs

Volumn 16, Issue 1, 2007, Pages 11-23

  Citterio, Paola ^a   Rucsoni, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Attachment inhibitors; CCR5; Chemokine inhibitors; Chemokines; CXCR4; Fusion inhibitors; HIV; In vitro synergy

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 4 CHLORO 6 FLUORO 2 SULFONAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; APLAVIROC; BENZAZOCINE DERIVATIVE; BMS 448043; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MARAVIROC; MICROBICIDE; MONOCLONAL ANTIBODY; PLACEBO; PRO 2000; PROTEIN INHIBITOR; STROMAL CELL DERIVED FACTOR 1BETA; SULFONAMIDE; T 1249; TAK 652; TNX 335; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; IN VITRO STUDY; LIFE CYCLE; LIVER TOXICITY; META ANALYSIS; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-HIV AGENTS; DRUGS, INVESTIGATIONAL; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5;

EID: 33845718113     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.1.11     Document Type: Review

References (93)

1. + cells. Science (1995) 270:1811-1815.
2. BEN-BARUCH A, MICHIEL DF, OPPENHEIM J et al.: Signal and receptors involved in recruitment of inflammatory cells. J. Biol. Chem. (1995) 270(20):11703-11706.
3. TACHIBANA K, HIROTA S, IIZASA I et al.: The chemokine receptor CXCR4 is essential for vascularization of gastrointestinal tract. Nature (1998) 393:591-594.
4. ZOU Y, KOTTMANN A, KURODA M et al.: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 393:595-596
5. CAO Y, QIN L, ZHANG L, SAFRIT J, HO DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. (1995) 332(4):201-208.
6. SHEARER GM, CLERICI M: Cytokine profiles in HIV type 1 disease and protection. AIDS Res. Hum. Retroviruses (1998) 14(Suppl. 2):S149-S152.
7. CLERICI M, BALOTTA C, SALVAGGIO A et al.: Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 88(2):574-579.
8. HADIDA F, VIEILLARD, V. AUTRAN B, CLARK-LEWIS I, BAGGIOLINI M, DEBRE P: HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3. J Exp. Med. (1998) 188(3):609-614.
9. FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science (1996) 272:872-877.
10. + cells is mediated by the chemokine receptor CC-CKR5. Nature (1996) 381:667-673.
11. DENG H, LIU R, ELLMEIER W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 318:661-666.
12. BLEUL CC, FARZAN M, CHOE H et al.: The lymphocytes chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382:829-833.
13. OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833-835.
14. CONNORS RI, SHERIDAN KE., CERADINI D, CHOE S, LANDAU NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. (1997) 185:621-628.
15. XIAO L, RUDOLPH DL, OWEN SM, SPIRA TJ, LAL RB: Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS (1998) 12(13):Fl37-F143.
16. VALENTIN A, ALBERT J, FENYO EM, ASJO B: Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. J. Virol. (1994) 68(10):6684-6689.
17. SIMMONS G, WILKINSON D, REEVES JD et al.: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. (1996) 70(12):8355-8360.
18. MCKNIGHT A, WEISS R: Blocking the docking of HIV-1. Proc. Natl. Acad. Sci. USA (2003) 100(19):10581-10582.
19. KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. (1998) 4:1302-1307.
20. LALEZARI J, HENRY K, O'HEARN M et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003) 348:2175-2185.
21. JACOBSON JM, LOWY I, FLETCHER CV et al: Single-dose safety, pharmacology, and antiviral activity of human immunodeficiency virus (HIV) type 1 entry inhibitor PR0542 in HIV-infected adults. J. Infect. Dis. (2000) 182:326-329.
22. LIN P-F, BLAIR W, WANG T et al.: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA (2003) 100:11013-11018.
23. FISCHER R, BERTONIS J, MEIER W et al.: HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 331:76-78.
24. DAAR ES, LI XL, MOUDGIL T, HO DD: High concentration of recombinant soluble CD4 are required to neutralize human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA (1990) 87:6574-6578.
25. SCHOOLEY RT, MERIGAN TC, GAUG P et al.: Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann. Intern. Med. (1990) 112:247-253.
26. RUSCONI S, SCOZZAEAVA A, MASTROLORENZO A, SUPURAN CT: New advances in HIV entry inhibitors development. Curr. Drug Targets Infect. Disord. (2004) 4:339-355.
27. NARDESE V, LONGHI R, POLO S et al.: Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat. Struct. Biol. (2001) 8(7):611-615.
28. PROUDFOOT AEI, POWER CA, HOOGEWERF AJ et al.: Extension of recombinant human RANTES by retention of the initiating methionine produces a potent antagonist. J. Biol Chem. (1996) 271:2599-2603.
29. SIMMONS G, CLAPHAM PR, PICARD L et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276:276-279.
30. MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. (1998) 187(8):1215-1224.
31. MOSIER DE, PICCHIO GR, GULIZIA RJ et al.: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. (1999) 73(5):3544-3550.
32. SABBE R, PICCHIO GR, PASTORE C et al.: Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J. Virol. (2001) 75(2):661-671.
33. HARTLEY O, GARTNER H, WILKEN J et al.: Medicinal chemistry applied to synthetic protein: development of highly potent HIV entry inhibitors. Proc. Natl. Acad, Sci. USA (2004) 23:16460-16465.
34. LEDERMAN M, VEAZEY R, OFFORD R et al.: Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 306:485-487.
35. YANG OO, SWANBERG SL, LU Z et al.: Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived-factor-1β correlates with down-regulation of CXCR4. J. Virol. (1999) 73:4582-4589.
36. RUSCONI S, MERRILL DP, LA SETA CATAMANCIO S et al.: In vitro inhibition of HIV-1 by Met-SDF-1β alone or in combination with antiretroviral drugs. Antiviral Ther. (2000) 5(3):199-204.
37. CHAN DC, KIM PS: HIV entry and its inhibition. Cell (1998) 93:681-684.
38. ECKERT DM, MALASHKEVICH VN, HONG LH, CARR PA, KIM PS: Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp4l coiled-coil pocket. Cell (1999) 99(1):103-115.
39. FERRER M, KAPOOR TM, STRASSMAIER T et al.: Selection of gp4l-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. (1999) 6(10):953-960.
40. ROOT MJ, KAY MS, KIM S: Protein design of an HIV-1 entry inhibitor. Science (2001) 291(5505):884-888.
41. LAMBERT DM, ZHOU J, MEDINAS R et al.: HIV-1 isolates from patients treated with T-20 are sensitive to the second generation fusion inhibitor T1249. Antiviral Ther. (1999) 4(Suppl. 1):8.
42. ARMAND-UGON M, CLOTET-CODINA I, TINTORI C et al.: The anti-HIV activity of ADS-J 1 targets the HIV-1 gp120. Virology (2005) 343:141-149.
43. ALLAWAY G, DAVIS-BRUNO KL, BEAUDRY GA et al.: Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses (1995) 11(5):533-539.
44. SHEARER WT, ISRAEL RJ, STARR S et al.: Recombinant CD4-IgG2 in human immunedeficiency virus type 1-infected children: Phase 1/2 study. J. Infect. Dis. (2000) 182:1774-1779.
45. JACOBSON JM, ISRAEL RJ, LOWY I et al.: Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. (2004) 48(2):423-429.
46. + cells. J. Virol. (1992) 66(8):4784-4793.
47. KURITZKES DR, JACOBSON J, POWDERLY WG et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. (2004) 189(2):286-291.
48. STIEGLER G, KATINGER H: Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J. Antimicrob. Chemotber. (2003) 51(4):757-759.
49. ARMBRUSTER C, STIEGLER GM, VCELAR BA et al.: A Phase 1 trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS (2002) 16(2):227-233.
50. STIEGLER G, ARMBRUSTER C, VCELAR B et al.: Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a Phase I evaluation. AIDS (2002) 16(15):2019-2025
51. WANG T, ZHANG Z, WALLACE OB et al.: Discovery of 4-benzoyl-1- [(4-methoxy-1 H- pyrrolo[2,3-blpyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. (2003) 46(20):4236-4239.
52. GUO Q, HO HT, DICKER I et al.: Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. (2003) 77(19):10528-10536.
53. SI Z, MADANI N, COX J et al.: Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Assoc. Sci. (2004) 101:5036-5041.
54. HO H, FAN L, NOWICKA-SANS B et al.: Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. (2006) 80:4017-4025.
55. VEAZEY RS, KLASSE PJ, SCHADER SM et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus cell fusion. Nature (2005) 438(7064):99-102.
56. HANNA G, LALEZARI J, HELLINGER J et al.: Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004):141 (Abstract).
57. RUSCONI S, MOONIS M, MERRILL DP et al.: Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. (1996) 40(1):234-236.
58. MAEDA K, NAKATA H, MIYAKAWA et al.: AK602: a novel HIV-specific spirodiketopiperazine CCR5 inhibitor potent against a wide spectrum of R5-HIV. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003):10 (Abstract)
59. LALEZARI J, THOMPSON M, KUMAR P et al.: Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS (2005) 19(14):1443-1448.
60. PECKHAM J, ANDERSON D, AQUINO C et al.: Design, synthesis and structure-activity relationship studies of novel 4,4-disubstituded piperidine based CCR5 antagonists as anti-HIV-1 agents. 230th American Chemical Society Meeting, Washington, DC, USA (2005).
61. IMAMURA S, ISHIHARA Y, HATTORI T et al.: CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives. Chem. Pharm. Bull. (Tokyo) (2004) 52(1):63-73.
62. IIZAWA Y, KANZAKI N, TAKASHIMA K et al.: Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonist. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003):11 (Abstract).
63. IMAMURA S, ICHIKAWA T, NISHIKAWA Y et al.: Discovery of the piperidine-4-carboxamide derivative TAK-220, a highly potent CCR5 antagonist anti-HIV-1 agent. 229th American Chemical Society Meeting, San Diego, USA (2005).
64. BABA M, KANZAKI N, MIYAKE H et al.: TAK-652, a novel small molecule CCR5 antagonist with potent anti-HIV-1 activity. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2005):541 (Abstract).
65. DORR P, MACARTNEY M, RICKETT G et al.: UK-427,857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003):12 (Abstract).
66. POZNIAK A, FÄTKENHEUER G, JOHNSON M et al.: Effect of short-term monotherapy with UK-427,857 on viral load in HIV-infected patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (2003):H-443 (Abstract).
67. FATKENHEUER G, POZNIAK A, JOHNSON M et al.: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. (2005) 11(11):1170-1172.
68. WESTBY M, LEWIS M, WHITCOMB J et al.: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. (2006) 80 (10):4909-4920.
69. MUIRHEAD G, ABEL S, RUSSELL D et al.: An investigation of the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK (2004):P283 (Abstract).
70. KIM D, WAMG L, HALE JJ et al.: Potent 1,3,4-trisubstituded pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties. Bioorg. Med. Chem. Lett. (2005) 15(8):2129-2134.
71. VEAZEY RS, KLASSE PJ, KETAS TJ et al.: Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-immunodeficiency virus infection. J. Exp. Med. (2003) 198(10):1551-1562.
72. AMIS F, GAVRILOV S, KAJUMO F et al.: Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. (2003) 77(9):5201-5208.
73. TAGAT J, McCOMBIE S, NAZARENO D et al.: Discovery of potent, selective, and orally active CCR5 antagonists for the potential treatment of HIV infection. 225th American Chemical Society Meeting, New Orleans, USA (2003).
74. OLSON WC, RABUT GEE, NAGASHIMA KA et al.: Differential inhibition of human immunodeficiency virus type 1 fusion, gp 120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. (1999) 73(5):4145-4155.
75. TRKOLA A, KETAS TJ, NAGASHIMA KA et al.: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO-140. J. Virol. (2001) 75(2):579-588.
76. NAGASHIMA KA, ROSENFIELD S, THOMPSON D et al.: Mechanisms of synergy between HIV-1 attachment, coreceptor and fusion inhibitors. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA (2001):310 (Abstract).
77. ROSCHKE V, CLARK S, BRANCO L et al.: Characterization of a panel of novel human monoclonal antibodies that specifically antagonize CCR5 and block HIV entry. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, USA (2004):H-213 (Abstract).
78. HOLMES MC, JOUVENOT Y, PEREZ E et al.: Towards gene knock out therapy for AIDS/HIV: targeted disruption of CCR5 using engineered zinc finger protein nucleases (ZFNs). 13th European Society of Gene Therapy, Prague, Czech Republic (2005).
79. SCHOLS D, ESTE' JA, HENSON G, DE CLERCQ E: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. (1997) 35(3):147-156.
80. DONZELLA GA, SCHOLS D, LIN SW et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. (1998) 4:72-77.
81. FRICKER SP, ANASTASSOV V, COX J et al.: Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem. Pharmacol. (2006) 72(5):588-586
82. DE CLERCQ E: Potential clinical application of the CXCR4 antagonist bicyclam of AMD3100. Mini Rev. Med. Chem. (2005) 5(9):805-824
83. HATSE S, PRINCEN K, BRIDGER G et al.: Specific CXCR4 antagonist with potent anti-HIV activity. Antiviral Res. (2002) 53:3.
84. MURAKAMI T, YOSHIDA A, KUMAKURA S et al.: KRH-2731-5HCL: a new potent and orally bioavailable X4 HIV-1 inhibiting CXCR4 antagonist in vivo. 15th International Conference on AIDS, Bangkok, Thailand (2004):LbOrAO1 (Abstract).
85. ROSENWIRTH B, DE BETHUNE MP, PTAK RG et al.: Debio-025, a novel non-immunosuppressive cyclosporine analog with potent anti-human immunodeficiency virus type 1 activity: pharmacological properties and mode of action. Antiviral Res. (2005) 65:3.
86. VAILLANT A, JUTEAU JM, LU HONG et al.: Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp4l core formation. Antimicrob. Agents Cbemother. (2006) 50(4):1393-1401.
87. DELMEDICO M, BRAY B, CAMMACK N et al.: Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. 13th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2006):48 (Abstract).
88. CHOU T-C, TALALAY P: Quantitative analysis of dose effect relationships: the combined effect of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. (1984) 22:27-55.
89. TREMBLAY CL, KOLLMAN C, GIGUEL F, CHOU T-C, HIRSCH MS: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blockcr AMD-3100. J. Acquir. Immune Defic. Syndr. (2000) 25(2):99-102.
90. TREMBLAY CL, GIGUEL F, KOLLMAN C et al.: Anti-human immunodeficiency interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemotber. (2002) 46(5):1336-1339.
91. RUSCONI S, LA SETA CATAMANCIO S, CITTERIO P et al.: Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. J. Virol. (2000) 74(19):9328-9332.
92. NAGASHIMA KA, THOMPSON DAD, ROSENFIELD SI, MADDON, PJ, DRAGIC T, OLSON WC: Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. (2001) 183:1121-1125.
93. PRINCEN K, HATSE S, VERMERE K et al.: Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J. Virol. (2004) 78(23):12993-13006.